The 10-second takeaway
For the quarter ended March 31 (Q4), PetMed Express missed estimates on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped. GAAP earnings per share grew significantly.
Margins grew across the board.
PetMed Express booked revenue of $51.1 million. The seven analysts polled by S&P Capital IQ expected a top line of $55.3 million on the same basis. GAAP reported sales were 8.6% lower than the prior-year quarter's $55.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.23. The seven earnings estimates compiled by S&P Capital IQ anticipated $0.21 per share. GAAP EPS of $0.23 for Q4 were 21% higher than the prior-year quarter's $0.19 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 35.7%, 180 basis points better than the prior-year quarter. Operating margin was 14.2%, 300 basis points better than the prior-year quarter. Net margin was 9.0%, 190 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $69.8 million. On the bottom line, the average EPS estimate is $0.21.
Next year's average estimate for revenue is $234.1 million. The average EPS estimate is $0.85.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 867 members out of 895 rating the stock outperform, and 28 members rating it underperform. Among 216 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 212 give PetMed Express a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on PetMed Express is hold, with an average price target of $11.92.
Can your portfolio provide you with enough income to last through retirement? You'll need more than PetMed Express. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add PetMed Express to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.